CoChat

Primary ciliary dyskinesia: a major player in a bigger game

Open access
Bhatt, Reena, Hogg, Claire · 2020 · Breathe

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

Primary ciliary dyskinesia (PCD) is an inherited disorder of clinical and genetic heterogeneity resulting from mutations in genes involved in the transport, assembly and function of motile cilia. The resulting impairment in mucociliary clearance means patients suffer from chronic progressive lung disease, bronchiectasis, rhinosinusitis and middle ear disease. Subfertility is common to both male and female patients. Situs abnormalities occur in around half of patients, with a subgroup suffering more complex situs arrangements where congenital heart defects or other organ abnormalities frequently coexist. Variations from the classical PCD phenotype are increasingly recognised where overlapping features across a range of motile and nonmotile ciliopathies are redefining our approach to both diagnosis and management of these complex conditions. PCD offers an ideal opportunity for direct visualisation of ciliary function and structure, following nasal brush biopsy, allowing opportunities for researchers to directly interrogate the downstream impact of loss of function mutations. In turn, this has led to rapid advances in the development of new diagnostic tests. These advances mean that PCD is an excellent disease model for understanding the genetic and mechanistic causes of the clinical phenotype for all respiratory ciliopathies. Furthermore, the overlapping role of motile ciliary defects in a wider set of complex and syndromic disorders related to loss of function mutations in primary, nonmotile cilia has been recognised. As we better understand the role of ciliary defects in a broad spectrum of diseases, we should aim to map out a framework through which we can identify, diagnose and treat all respiratory ciliopathies. Key points: Primary ciliary dyskinesia is just one of a group of conditions where a heterogeneous array of genetic mutations affect the assembly or structure of motile cilia. Overlapping phenotypes between motile and nonmotile ciliopathies are redefining the diagnostic and therapeutic approach to encompass all ciliopathy patients with a respiratory phenotype. An extended diagnostic algorithm may be required to capture the majority of cases with a respiratory ciliopathy, including patients with syndromic ciliopathies. The terminology around disorders of motile cilia is becoming more descriptive to better reflect the heterogeneity and underlying disease mechanisms across the spectrum of respiratory ciliopathies. Educational aims: To summarise the existing knowledge base around the disease mechanisms for respiratory ciliopathies, including primary ciliary dyskinesia (PCD). To explore and understand the reasons for changing terminology around respiratory ciliopathies. To emphasise key messages around the diagnosis and treatment of all ciliopathies. Diagnosing PCD is complex and time consuming, and there is no single stand-alone test that can confirm or exclude a diagnosis in all cases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/20734735.0047-2020

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flowchart to demonstrate the pathways to diagnosis of PCD as per the a) European Respiratory Society and b) American Thoracic Society consensus statements. It is important to note that not all patients will require all investigations. #: cystic fibrosis (CF) should be ruled out before performing nasal nitric oxide (nNO) measurement, as roughly one-third of CF patients can have nNO values below PCD diagnostic cut-offs. nNO measurements should only be performed with chemiluminescence analysers using standardised protocols at centres with specific expertise in nNO measurements. Some nNO analysers have not received approval from federal agencies worldwide (US Food and Drug Administration and Health Canada), which may have implications for clinical implementation. ¶: genetic panel testing for mutations in >12 disease-associated PCD genes, including deletion/duplication analysis. +: as nNO levels can be significantly decreased by viral respiratory tract infections, a repeat nNO measurement, at least 2 weeks after the initial low value (expert opinion), is recommended to ensure the initial low value is not secondary to a viral process. A normal nNO value upon repeat testing is not suggestive of PCD, as nNO values remain consistently low in PCD. §: most forms of PCD resulting in normal nNO levels have normal or non-diagnostic electron microscopy studies. Thus, genetic testing is recommended in these cases. ƒ: or presence of variants of unknown significance. ##: additional corroborative testing may provide information on clinical prognosis, further disease understanding, and potential future therapeutic considerations. ¶¶: known disease-associated TEM ultrastructural defects include outer dynein arm (ODA) defects, ODA plus inner dynein arm (IDA) defects, IDA defect with microtubular disorganisation, and absent central pair, identified using established criteria. Of note, the presence of IDA defects alone is rarely diagnostic for PCD. ++: up to 30% of PCD cases can have normal ciliary ultrastructure on electron microscopy. Consider referral to PCD specialty centre if there is a strong clinical phenotype but all electron microscopy and genetic testing are negative. HSVMA: high-speed video microscopy analysis. Reproduced from [29] with permission.
Figure 1 Flowchart to demonstrate the pathways to diagnosis of PCD as per the a) European Respiratory Society and b) American Thoracic Society consensus statements. It is important to note that not all patients will require all investigations. #: cystic fibrosis (CF) should be ruled out before performing nasal nitric oxide (nNO) measurement, as roughly one-third of CF patients can have nNO values below PCD diagnostic cut-offs. nNO measurements should only be performed with chemiluminescence analysers using standardised protocols at centres with specific expertise in nNO measurements. Some nNO analysers have not received approval from federal agencies worldwide (US Food and Drug Administration and Health Canada), which may have implications for clinical implementation. ¶: genetic panel testing for mutations in >12 disease-associated PCD genes, including deletion/duplication analysis. +: as nNO levels can be significantly decreased by viral respiratory tract infections, a repeat nNO measurement, at least 2 weeks after the initial low value (expert opinion), is recommended to ensure the initial low value is not secondary to a viral process. A normal nNO value upon repeat testing is not suggestive of PCD, as nNO values remain consistently low in PCD. §: most forms of PCD resulting in normal nNO levels have normal or non-diagnostic electron microscopy studies. Thus, genetic testing is recommended in these cases. ƒ: or presence of variants of unknown significance. ##: additional corroborative testing may provide information on clinical prognosis, further disease understanding, and potential future therapeutic considerations. ¶¶: known disease-associated TEM ultrastructural defects include outer dynein arm (ODA) defects, ODA plus inner dynein arm (IDA) defects, IDA defect with microtubular disorganisation, and absent central pair, identified using established criteria. Of note, the presence of IDA defects alone is rarely diagnostic for PCD. ++: up to 30% of PCD cases can have normal ciliary ultrastructure on electron microscopy. Consider referral to PCD specialty centre if there is a strong clinical phenotype but all electron microscopy and genetic testing are negative. HSVMA: high-speed video microscopy analysis. Reproduced from [29] with permission.CC BY-NC · PubMed Central
Figure 2 TEM images of cross-sections of cilia from nasal brushing samples. a) Normal; b) outer and inner dynein arm defects; c) inner dynein arm defects plus microtubular disorganisation; d) central pair defect; and e) transposition defect.
Figure 2 TEM images of cross-sections of cilia from nasal brushing samples. a) Normal; b) outer and inner dynein arm defects; c) inner dynein arm defects plus microtubular disorganisation; d) central pair defect; and e) transposition defect.CC BY-NC · PubMed Central
Figure 3 IF staining in a healthy control where a) tubulin stains green to indicate presence of cilia on the cell surface, and b) staining with DNAH5 antibody for the outer dynein arm (ODA) in red is identical, indicating normal ODA structure; and in c) and d) a patient with DNAH11 mutations, where c) tubulin staining green for cilia is seen whereas in d) absence of staining for DNAH11 using red labelled antibody is evident.
Figure 3 IF staining in a healthy control where a) tubulin stains green to indicate presence of cilia on the cell surface, and b) staining with DNAH5 antibody for the outer dynein arm (ODA) in red is identical, indicating normal ODA structure; and in c) and d) a patient with DNAH11 mutations, where c) tubulin staining green for cilia is seen whereas in d) absence of staining for DNAH11 using red labelled antibody is evident.CC BY-NC · PubMed Central
Figure 4 3D electron tomography series demonstrating the clear difference between the healthy control sample and that from a patient with HYDIN mutation. a) Schematic interpretation of the central pair of a normal cilia highlighting the C2b protein that is absent in patients with HYDIN (red circle). b) 3D tomogram of healthy control showing normal appearance of C2b in the central complex and c) 3D tomogram from a patient with HYDIN showing absence of C2b.
Figure 4 3D electron tomography series demonstrating the clear difference between the healthy control sample and that from a patient with HYDIN mutation. a) Schematic interpretation of the central pair of a normal cilia highlighting the C2b protein that is absent in patients with HYDIN (red circle). b) 3D tomogram of healthy control showing normal appearance of C2b in the central complex and c) 3D tomogram from a patient with HYDIN showing absence of C2b.CC BY-NC · PubMed Central
Figure 5 Tomogram from a patient with DNAH11 mutation showing loss of ODA protein proximally in first image, and where the missing protein would be located in second image in red. The third image shows normal outer dynein arm structure in a patient with microtubular disorganisation (MTD).
Figure 5 Tomogram from a patient with DNAH11 mutation showing loss of ODA protein proximally in first image, and where the missing protein would be located in second image in red. The third image shows normal outer dynein arm structure in a patient with microtubular disorganisation (MTD).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Cited by

See all 35

Metadata

Authors
Bhatt, R., & Hogg, C.
Affiliations
Royal Brompton Hospital (GB)
Corresponding author
Hogg, Claire
Venue
Breathe
Published
2020-06
Volume
16
Issue
2
Pages
200047
ISSN
  • 1810-6838 (ISSN-L)
  • 2073-4735
OpenAlex
W3089058177
Cited by
25
References
58
Citations by year
2026: 1 · 2025: 3 · 2024: 5 · 2023: 8 · 2022: 5 · 2021: 3
FWCI
0.56
Type
journal article
Language
en
Open access
Locations
  • Breathe (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
University of Dundee
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
primary ciliary dyskinesia, motile cilia, ciliopathies, mucociliary clearance, congenital heart disease, subfertility, ciliary function, genetic heterogeneity, diagnostic algorithm, disease terminology, bronchiectasis, sinusitis, middle ear disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary ciliary dyskinesia: a major player in a bigger game. https://app.cochat.ai/papers/10.1183/20734735.0047-2020
The paper
Bhatt, R., & Hogg, C. (2020). Primary ciliary dyskinesia: a major player in a bigger game. Breathe. https://doi.org/10.1183/20734735.0047-2020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.